Stem cell clinic red flags include promises of a cure or “no side effects,” one product pitched for unrelated diseases, testimonials offered as proof, and vague answers about what you’ll receive. Also watch for rushed consent, registration passed off as approval, pressure to pay, and no plan for complications. If a clinic won’t name the product or let you verify its claims before paying, put the decision on hold.
Stem cell clinic red flags at a glance
| What you notice | What to ask for |
|---|---|
| One product for unrelated diseases | Evidence for your condition and the proposed route of administration. |
| “Guaranteed” or “no risk” | Known risks, uncertainties, and alternatives. |
| Testimonials instead of results | A human study that matches the product and intended use. |
| Vague product details | Product name, source, dose, route, and testing information. |
| Rushed consent or unnamed oversight | A consent form to review and the name of the responsible clinician. |
| “Registered” presented as “approved” | The official record and an explanation of what it covers. |
| Pressure to pay | An itemized quote, refund terms, and time for a second opinion. |
| No follow-up plan | Scheduled checks, an urgent contact, and a plan for complications. |
One product for unrelated diseases
If a clinic offers the same injection for knee pain and a neurological condition, ask what evidence supports each use. Even an approved product has a defined use. In the United States, look up the exact product on the FDA’s approved cellular and gene therapy products list, then open its product page and compare the indication with the clinic’s written offer.[1]

What an approval check looks like
On the FDA’s RYONCIL page, the indication specifies steroid-refractory acute graft-versus-host disease in children aged 2 months and older. A clinic citing that approval to support an injection for knee pain would be pointing to a real approval for a different use. Match the product and the condition, then check the label for the patient group and route. A match tells you what was approved; it doesn’t tell you whether treatment is right for you.[2]
Cure promises and testimonials as proof
Ask anyone promising “no side effects” to put the known risks and uncertainties in writing. The FDA has received reports of serious harms associated with unapproved regenerative medicine products, including blindness, tumor formation, and infections. Those reports are a reason to ask about the risks of the specific product and procedure; they don’t establish how often a complication occurs.[3]
A recovery video can show how one person felt, but it can’t tell you whether the treatment caused the improvement. Ask for published human results for the same condition, product, and delivery method. Check who took part, how many people were studied, whether there was a comparison group, what outcomes were measured, how long follow-up lasted, and what harms were reported. A trial listing is not a result. If results aren’t available, the clinic should say so rather than present an experimental treatment as proven.
Vague answers about what you’ll receive
Ask for the exact product name, cell type and tissue source, dose, route, number of sessions, and what testing a batch must pass before use. If the clinic says “your own cells,” ask which tissue they come from; if it uses donor cells, ask how donors are screened. The distinction between autologous and allogeneic cells helps you ask the right question. If the offer is for exosomes, don’t accept a study of living stem cells as evidence for that product.
Testing matters even if a vial looks normal. In a 2018 U.S. outbreak involving an unapproved umbilical cord blood-derived product, all 12 patients with reported bacterial infections were hospitalized and none died. The longest initial hospital stay reported was 58 days. Investigators found bacteria in unopened vials. The report describes one outbreak, not the infection rate for all cell treatments.[4]
Rushed consent or unclear oversight
Ask for a consent form you can review at home in a language you understand. It should explain what’s proposed, the known and uncertain risks, alternatives, and what happens if you decline. Get the treating clinician’s name. If the clinic says a committee approved the protocol, ask which committee reviewed it and request the written decision. Don’t sign while you’re being pressed to decide.
Registration passed off as approval
In the United States, an FDA registration or a ClinicalTrials.gov listing is not FDA product approval. If the clinic says the intervention is investigational, ask for the study ID and sponsor, and check that the listed location and intervention match the offer. A listing alone does not show that the product can be marketed or that it works.[3]
In Japan, distinguish an approved product from a clinic service offered under a filed regenerative medicine plan. For a product claim, start with the Pharmaceuticals and Medical Devices Agency’s approved product information.[5] The Ministry of Health, Labour and Welfare explains the separate routes for treatment and research plans. Filing a treatment plan is not product marketing approval or proof of benefit.[6] For a filed plan, ask for the plan number and compare the provider and treatment name with the ministry’s public listings.[7] For a research claim, look up the study in the Japan Registry of Clinical Trials (jRCT).[8]
If a clinic shows you a plan for one facility but asks you to book at another, ask for the record that covers the site where you’ll actually be treated. The guide to regenerative medicine registration in Japan explains the documents you may encounter.
Pressure to pay
A same-day deposit, a discount that expires before you can ask your doctor, or a treatment fee presented as the price of joining a trial all warrant a pause. If it’s called research, ask which costs the sponsor covers and which you would owe. The FDA warns U.S. patients about charges for unapproved regenerative products outside supervised trials; the label “trial” on an invoice doesn’t settle the question.[3]
Get an itemized quote covering testing, the procedure, and follow-up. Ask what’s refundable if you’re ineligible, a batch fails testing, or you cancel. Find out separately who would pay for emergency care.
No plan for complications or follow-up
Before treatment, get the follow-up dates and ask who answers urgent calls after hours. Ask what symptoms require immediate care and where to go for it. If you’re traveling, confirm who gets your records and which clinician can see you after you return. The guide to planning treatment travel in Japan covers arranging that handover.
What to do before you book
You don’t need to count red flags. If the product, regulatory claim, or emergency plan can’t be verified, hold off on paying or signing. Take the written offer, consent form, and any study or plan number to a clinician who treats your condition and has no financial stake in the offer. If you’re comparing treatment facilities in Japan, use the same questions for each one.
Regulatory and public-health sources checked on . Check the current record before relying on an approval, plan, or trial listing.
For logistical questions about care in Japan, contact the patient support team. For an independent opinion on the treatment, speak with your own clinician.




